{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:13:32Z","timestamp":1767388412141,"version":"3.48.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104959","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:07:45Z","timestamp":1758589665000},"page":"104959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Maintenance after first-line treatment for advanced soft tissue sarcoma"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-1548","authenticated-orcid":false,"given":"Nicolas","family":"Penel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104959_bib1","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1158\/1078-0432.CCR-18-0851","article-title":"Nilotinib as coadjuvant treatment with doxorubicin in patients with sarcomas: a phase I trial of the spanish group for research on sarcoma","volume":"24","author":"Alemany","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib2","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/cncr.30661","article-title":"REGOSARC: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis","volume":"123","author":"Berry","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0959-8049(02)00480-X","article-title":"Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy","volume":"39","author":"Blay","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib4","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1158\/1078-0432.CCR-08-0336","article-title":"Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma","volume":"14","author":"Blay","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/cam4.1931","article-title":"Very long-term survivors among patients with metastatic soft tissue sarcoma","volume":"8","author":"Carbonnaux","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104959_bib6","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib7","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-24-1037","article-title":"Safety and efficacy of the combination lurbinectedin plus doxorubicin from a phase 1b trial in patients with advanced\/metastatic soft-tissue sarcoma","volume":"30","author":"Cote","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14796694.2025.2463798","article-title":"SaLudo: a randomized phase IIb\/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma","volume":"21","author":"Cote","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib9","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D'Adamo","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejca.2011.12.008","article-title":"First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I\/II open-label and double-blind study","volume":"48","author":"Demetri","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib11","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib14","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","article-title":"Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial","volume":"36","author":"Harter","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104959_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejca.2020.10.032","article-title":"A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS)","volume":"144","author":"Lewin","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib19","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1158\/1078-0432.CCR-23-3983","article-title":"First-line anlotinib treatment for soft-tissue sarcoma in chemotherapy-ineligible patients: an open-label, single-arm, phase 2 clinical trial","volume":"30","author":"Li","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib20","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib21","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0277-5379(87)90089-7","article-title":"Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II\/phase III study of the EORTC soft tissue and bone sarcoma group","volume":"23","author":"Mouridsen","year":"1987","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib23","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/bjc.1998.735","article-title":"High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group","volume":"78","author":"Nielsen","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib24","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104959_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.03.024","article-title":"Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial","author":"Penel","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib27","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104959_bib29","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"Picasso III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib30","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib31","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104959_bib32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2025.104959_bib33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104959_bib34","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-22-1903","article-title":"Anlotinib plus epirubicin followed by anlotinib maintenance as first-line treatment for advanced soft-tissue sarcoma: an open-label, single-arm, phase II trial","volume":"28","author":"Wang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104959_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.critrevonc.2025.104959_bib36","doi-asserted-by":"crossref","first-page":"11501","DOI":"10.1200\/JCO.2025.43.16_suppl.11501","article-title":"Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): a randomized, Double-Blind, Parallel-Controlled, phase III study","volume":"43","author":"Zhou","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:10:25Z","timestamp":1767388225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S1040842825003476"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104959","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance after first-line treatment for advanced soft tissue sarcoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104959"}}